和黃醫藥(00013.HK):在中國啟動新型SHP2抑制劑HMPL-415用於治療晚期惡性實體瘤的I期臨牀試驗
格隆匯7月10日丨和黃醫藥(00013.HK)發佈公吿,在中國啟動HMPL-415的I期臨牀試驗。HMPL-415是一種靶向Src同源2結構域的蛋白酪氨酸磷酸酶2(“SHP2”)的新型、研究性的選擇性變構抑制劑。首名患者已於2023年7月6日接受首次給藥治療。
該項研究是一項多中心、開放標籤的臨牀試驗,旨在評估HMPL-415作為單藥療法治療晚期惡性實體瘤的安全性、耐受性、藥代動力學和初步療效特徵。研究供計劃納入最多約80名患者,其中包括作為劑量遞增階段的患者,以及按照確定的II期臨牀試驗推薦劑量(RP2D)接受給藥的額外患者。主要研究者是復旦大學附屬中山醫院的劉天舒醫生及湖南省腫瘤醫院的楊農醫生。該項研究的其他詳情可登錄clinicaltrials.gov,檢索註冊號NCT05886374查看。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.